The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

Publications

Hotta T, Okimoto T, Hamaguchi M, Tsubata Y, Isobe T

Acute Interstitial Lung Disease Induced by Rechallenge with Ceritinib.

Internal medicine (Tokyo, Japan) 2020 Jan 15;59;253-256 — 2020 Jan 15 — 253-256

Gaillard CM, Chumbi-Flores W, Gaillot-Durand L, Craighero F, Devouassoux G, Kiakouama-Maleka L

[Diffuse infiltrative lung disease, pericarditis, pleural effusion and ceritinib hypersensitivity].

Revue des maladies respiratoires 2019 Sep;36 — 2019 Sep — 902-905

Bender L, Meyer G, Quoix E, Mennecier B

Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report.

Annals of translational medicine 2019 Mar;7;106 — 2019 Mar — 106

Lim SM, An HJ, Park HS, Kwon HJ, Y Kim E, Hur J, Moon YW

Organizing pneumonia resembling disease progression in a non-small-cell lung cancer patient receiving ceritinib: A case report.

Medicine 2018 Aug;97;e11646 — 2018 Aug — e11646

Joshi AP, Chandrakanth MV, Noronha V, Patil V, Chougule A, Mahajan A, Janu AK, Chanana R, Prabhash K

Ceritinib in anaplastic lymphoma kinase-positive nonsmall cell lung cancer among patients who were previously exposed to crizotinib: Experience from the Indian subcontinent.

Indian journal of cancer 2017 Jan-Mar;54;144-147 — 2017 Jan-Mar — 144-147

Pellegrino B, Facchinetti F, Bordi P, Silva M, Gnetti L, Tiseo M

Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature.

Clinical lung cancer 2018 03;19;e151-e161 — 2018 03 — e151-e161

Au TH, Cavalieri CC, Stenehjem DD

Ceritinib: A primer for pharmacists.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2017 Dec;23;602-614 — 2017 Dec — 602-614